QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Advaxis, Inc. (ADXS) Presentation Highlights Superior Approach To Fighting Cancer 0 comments
    Jan 30, 2013 10:40 AM | about stocks: ADXS

    Thomas A. Moore, the Chairman and CEO of Advaxis, a New Jersey based biotech company focused on using bio-engineered bacteria to help the immune system fight cancer and other diseases, recently gave a presentation at the 6th Annual OneMedForum Conference, a platform for the newest ideas and companies in health and medicine. The presentation provided an opportunity to summarize the goals, unique strengths, and accomplishments of Advaxis as it helps lead what is becoming a revolution in the treatment of cancer and infectious diseases.

    Mr. Moore showed how Advaxis is an immunotherapy company that is different in that, through use of a genetic immune response against a safe version of a common pathogen, the company's platform technology is designed to:

    • Drive a more comprehensive therapeutic response

    • Overcome tumor protection mechanisms at the tumor as in no other treatment

    • Create "epitope spreading" beyond targeted antigens, a sort of immune memory for long term effects

    Mr. Moore emphasized that this superior technology for fighting cancer is a very well developed, with many peer reviewed papers and over 70 issued and pending patents. As an immunotherapy based therapy, it is not a poison based approach such as chemotherapy, where healthy cells are killed in attacking disease cells. It's an approach that can work throughout all parts of the body at the same time, since it is based upon the body's own immune system.

    The Advaxis approach leads to a 300% increase in killer T cells present in the tumor, while simultaneously reducing by a full 80% the number of cells around the tumor that tend to deactivate killer T cells. The approach also turns the immune system on in such a way that it enables it to attack new targets. Initial results are encouraging, with animal studies showing a 75% tumor reduction. In addition, early safety studies on humans have shown no adverse effects.

    For additional information, visit Advaxis.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ADXS
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.